MSACL 2019 US Abstract

Screening for Alzheimer’s Disease: Summary and Future Directions of an Amyloid-Beta Blood Test

Melissa Budelier, Suzanne Schindler, Yan Li, Jim Bollinger, Vitaliy Ovod, Kwasi Mawuenyega, Randall Bateman
Washington University, St Louis, MO

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Melissa Budelier (Presenter) Washington University in St Louis

Presenter Bio: Melissa Budelier is a Clinical Chemistry Fellow at Washington University and a Post-Doctoral fellow in the Bateman Laboratory. As a future medical director of a clinical chemistry laboratory, Melissa’s goal is to expand the utility of peptide and protein mass spectrometry in laboratory medicine. She is passionate about helping researchers bridge the gap between identification of a potential biomarker, and implementation of a useful clinical test. Her research interests include improving early detection, and subsequently treatment, of neurodegenerative diseases.

Relevant Financial Disclosures (within past 24 months) Honorarium/Expenses Washington University in St Louis Salary Washington University in St Louis. Dr. Bateman receives income from C2N Diagnostics for serving on the scientific advisory board. He consults for Roche, Genentech, AbbVie, Pfizer, Boehringer-Ingelheim, and Merck. Royalty / IP / Other Income Dr. Bateman co-founded C2N Diagnostics. Washington University and Dr. Bateman have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. Washington University, with Dr. Bateman as co-inventor, have submitted the US provisional patent application “Plasma Based Methods for Detecting CNS Amyloid Deposition.” Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

A non-invasive, inexpensive screening test for Alzheimer disease (AD) is needed to advance clinical and prevention trials. We have developed an immunoprecipitation mass spectrometry (IPMS) blood test that is sensitive and specific for amyloid-beta (Aβ) peptides 1-42 and 1-40. In multiple cohorts, Aβ42/Aβ40 as measured by IPMS is significantly decreased in amyloid PET-positive individuals compared to amyloid PET-negative individuals. A logistic regression model for prediction of amyloid PET status by plasma Aβ42/Aβ40 had a ROC AUC of 0.88, which increased to 0.95 when APOE ε4 status and age were included in the model. A single assay for plasma Aβ42/Aβ40 and APOE ε4 status would reduce screening costs for enrolling participants in AD drug trials and has the potential to be used in clinical diagnosis.